Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836826 + Ibrutinib in R/R CLL
NCT02759016Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BI 836826 in chronic lymphocytic leukemia (CLL), sponsored by Boehringer Ingelheim. Primary endpoints: Recommended Phase 2 Dose at 4 weeks and Dose Limiting Toxicities at 4 weeks. Started Jun 2016; status: completed.
02
Drugs
BI 836826
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02759016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759016.